Advertisement

Topics

EC Approves Sandoz Biosimilar of MabThera to Treat Blood Cancers

09:33 EDT 19 Jun 2017 | PharmPro

Sandoz receives approval in Europe for Rixathon (biosimilar rituximab) to treat blood cancers and immunological diseases. Sandoz now has four biosimilars approved in Europe.
Contributed Author: 
Novartis International AG
Topics: 

Original Article: EC Approves Sandoz Biosimilar of MabThera to Treat Blood Cancers

NEXT ARTICLE

More From BioPortfolio on "EC Approves Sandoz Biosimilar of MabThera to Treat Blood Cancers"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...